Role of stem cells in spondyloarthritis: Pathogenesis, treatment and complications

Wong, Rebecca S. Y.

doi:10.1016/j.humimm.2015.09.038

Cited by 7 publications

(4 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The safety and efficacy of mesenchymal stem cell therapy for autoimmune diseases, such as Systemic Lupus Erythematosus (SLE) and Multiple Sclerosis (MS), have been confirmed through multiple studies ( 49 – 51 ). Several clinical trials using mesenchymal stem cell transplantation to treat AS are currently underway to evaluate the safety and clinical effects of the transplantation in AS patients ( 8 , 50 ). Current clinical trials and literature reports on stem cell therapy for AS indicate that MSC are safe and effective for the treatment of the disease.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of preclinical efficacy of human umbilical cord mesenchymal stem cells in ankylosing spondylitis

Shen

Wang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

ObjectiveUmbilical cord mesenchymal stem cells (UCMSCs) have significant regenerative, tissue repair, and immunomodulatory properties that can help reduce inflammatory responses in patients with ankylosing spondylitis (AS). In this study, we used a combination of bovine proteoglycan and dimethyldioctadecylammonium (DDA) to establish a mouse model of proteoglycan-induced spondylitis (PGISp). To evaluate the therapeutic effects of UCMSCs, we treated PGISp mice with different doses of hUCMSCs via tail vein injection.MethodsAt week 13, the PGISp mice exhibited thickened, erythematous paws, erythema in the extremities, and lameness. CT scans revealed necrotic lysis of chondrocytes, formation of fissures, visible hemorrhage, connective tissue hyperplasia, and focal infiltration of lymphocytes in the intervertebral discs. At week 14, the PGISp mice were randomly divided into three groups and administered different doses of hUCMSCs (0.25, 0.5, and 1.0×107 cells/kg, iv, QOW×2, n=10). To assess the therapeutic effects of hUCMSCs, we evaluated Th cell subsets in the spleen, spleen and thymus coefficients, peripheral blood inflammatory factors, and pathological and imaging observations of the spines and lumbar spines in the PGISp mice.ResultsThe results demonstrated that injection of hUCMSCs shifted the balance axis between Th1 and Th2 cells in the spleen towards Th2 cells. Moreover, the spleen coefficient and levels of inflammatory cytokines (TNF-α and CCL-2) in the serum decreased after hUCMSC injection. CT imaging and pathological analysis indicated that hUCMSC treatment inhibited ectopic osteogenesis and maintained clear small joint gaps, which slowed down the progression of structural lesions in the disc, nucleus pulposus, fibrous ring, and cartilage in PGISp mice.ConclusionAdministering hUCMSCs at the 14th week after modeling proved to be an effective treatment for PGISp mice. This experiment offers a valuable reference for the pre-clinical use of hUCMSCs in the treatment of AS.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of preclinical efficacy of human umbilical cord mesenchymal stem cells in ankylosing spondylitis

Shen

Wang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…However, the use of biologics is often accompanied by serious side effects such as life-threatening infections [17]. Some researchers have also explored the role of stem cell-based therapies in SpA (reviewed by Wong) [18]. Nevertheless, more research and exploration are necessary before stem cell-based therapies are used widely in the treatment of SpA.…”

Section: Spondyloarthritismentioning

confidence: 99%

Disease-Modifying Effects of Long-Term and Continuous Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Spondyloarthritis

Wong

2019

Advances in Pharmacological Sciences

View full text Add to dashboard Cite

Spondyloarthritis or spondyloarthropathy (SpA) is a group of related rheumatic disorders, which presents with axial and nonaxial features, affecting structures within the musculoskeletal system, as well as other bodily systems. Both pharmacological and nonpharmacological therapeutic options are available for SpA. For decades, nonsteroidal anti-inflammatory drugs (NSAIDs) have been used as the first-line drugs to treat the disease. Research has shown that other than pain relief, NSAIDs have disease-modifying effects in SpA. However, to achieve these effects, continuous and/or long-term NSAID use is usually required. This review will give an overview of SpA, discuss NSAIDs and their disease-modifying effects in SpA, and highlight some of the important adverse effects of long-term and continuous NSAID use, particularly those related to the gastrointestinal, renal, and cardiovascular systems.

show abstract

“…However, there were complications of hematopoietic stem cells transplantation in the treatment of autoimmune diseases, which included availability, treatment-related mortality, infective and endocrinological complications, treatmentassociated toxicity, and secondary autoimmune diseases and malignancies (71,72). MSCs, on the contrary, could represent a future treatment, with a possible safe and tolerable profile, for inflammatory arthritis such as SpAs.…”

Section: Reviewmentioning

confidence: 99%

Mesenchimal stem cells: a possible role in the pathogenesis and treatment of spondyloarthritis

et al. 2017

View full text Add to dashboard Cite

SUMMARY Spondyloarthritis (SpAs) are a group of chronic inflammatory diseases that affect joints and enthesis with a possible involvement of other districts such as skin, eye and bowel. In SpAs, the inflammatory process could lead to both erosive damage (as in peripheral joint involvement of psoriatic arthritis), or bone formation (as in ankylosing spondylitis) with a reduction in function and quality of life. Recently, Mesenchimal stem cells (MSCs) transplant was used in different diseases, including autoimmune and inflammatory diseases, with the aim of repairing tissue damage, exploiting their regenerative capacity. However, MSCs also proved to have an immune-modulatory capacity due to their interaction with the cells of the immune system. The aim of this brief paper was to review the possible pathogenic role and the new perspective of MSCs use in SpAs.

show abstract

Role of stem cells in spondyloarthritis: Pathogenesis, treatment and complications

Cited by 7 publications

References 85 publications

Evaluation of preclinical efficacy of human umbilical cord mesenchymal stem cells in ankylosing spondylitis

Evaluation of preclinical efficacy of human umbilical cord mesenchymal stem cells in ankylosing spondylitis

Disease-Modifying Effects of Long-Term and Continuous Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Spondyloarthritis

Mesenchimal stem cells: a possible role in the pathogenesis and treatment of spondyloarthritis

Contact Info

Product

Resources

About